Ute Reuning

Klinikum rechts der Isar — Germany

Medicine · Health Sciences

36h-index5.2kcitations137works2.82yr avg
OpenAlex↗ORCID↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Cell Adhesion Molecules Research(50), Protease and Inhibitor Mechanisms(49), Monoclonal and Polyclonal Antibodies Research(29), Blood Coagulation and Thrombosis Mechanisms(25), Chemokine receptors and signaling(18)

Publications137 total

Switching Roles─Exploring Concentration-Dependent Agonistic versus Antagonistic Behavior of Integrin Ligands
Journal of Medicinal Chemistry·2025· 3 citedOpen Access
The chemokine CX3CL1 promotes intraperitoneal tumour growth despite enhanced T-cell recruitment in ovarian cancer
Neoplasia·2025· 6 citedOpen Access
Importance of integrin transmembrane helical interactions for antagonistic versus agonistic ligand behavior: Consequences for medical applications
Bioorganic Chemistry·2025· 2 cited
CRISPR/Cas9-mediated knock out of ITGB6 in human OSCC cells reduced migration and proliferation ability
Head & Face Medicine·2024· 2 citedOpen Access
CHD4 acts as a prognostic factor and drives radioresistance in HPV negative HNSCC
Scientific Reports·2024· 1 citedOpen Access
Table S1 from The Chemokine CX3CL1 Improves Trastuzumab Efficacy in HER2 Low–Expressing Cancer <i>In Vitro</i> and <i>In Vivo</i>
2023Open Access
Figure S3 from The Chemokine CX3CL1 Improves Trastuzumab Efficacy in HER2 Low–Expressing Cancer <i>In Vitro</i> and <i>In Vivo</i>
2023Open Access
Figure S3 from The Chemokine CX3CL1 Improves Trastuzumab Efficacy in HER2 Low–Expressing Cancer <i>In Vitro</i> and <i>In Vivo</i>
2023Open Access
Figure S6 from The Chemokine CX3CL1 Improves Trastuzumab Efficacy in HER2 Low–Expressing Cancer <i>In Vitro</i> and <i>In Vivo</i>
2023Open Access
Figure S2 from The Chemokine CX3CL1 Improves Trastuzumab Efficacy in HER2 Low–Expressing Cancer <i>In Vitro</i> and <i>In Vivo</i>
2023Open Access
Figure S5 from The Chemokine CX3CL1 Improves Trastuzumab Efficacy in HER2 Low–Expressing Cancer <i>In Vitro</i> and <i>In Vivo</i>
2023Open Access
Figure S7 from The Chemokine CX3CL1 Improves Trastuzumab Efficacy in HER2 Low–Expressing Cancer <i>In Vitro</i> and <i>In Vivo</i>
2023Open Access
Figure S1 from The Chemokine CX3CL1 Improves Trastuzumab Efficacy in HER2 Low–Expressing Cancer <i>In Vitro</i> and <i>In Vivo</i>
2023Open Access
Figure S1 from The Chemokine CX3CL1 Improves Trastuzumab Efficacy in HER2 Low–Expressing Cancer <i>In Vitro</i> and <i>In Vivo</i>
2023Open Access
Figure S4 from The Chemokine CX3CL1 Improves Trastuzumab Efficacy in HER2 Low–Expressing Cancer <i>In Vitro</i> and <i>In Vivo</i>
2023Open Access
Data from The Chemokine CX3CL1 Improves Trastuzumab Efficacy in HER2 Low–Expressing Cancer <i>In Vitro</i> and <i>In Vivo</i>
2023Open Access
Figure S4 from The Chemokine CX3CL1 Improves Trastuzumab Efficacy in HER2 Low–Expressing Cancer <i>In Vitro</i> and <i>In Vivo</i>
2023Open Access
Figure S6 from The Chemokine CX3CL1 Improves Trastuzumab Efficacy in HER2 Low–Expressing Cancer <i>In Vitro</i> and <i>In Vivo</i>
2023Open Access
Figure S5 from The Chemokine CX3CL1 Improves Trastuzumab Efficacy in HER2 Low–Expressing Cancer <i>In Vitro</i> and <i>In Vivo</i>
2023Open Access
Figure S7 from The Chemokine CX3CL1 Improves Trastuzumab Efficacy in HER2 Low–Expressing Cancer <i>In Vitro</i> and <i>In Vivo</i>
2023Open Access
page 1 of 7Next →

Frequent Co-authors

Manfred Schmitt(22), Horst Kessler(18), Viktor Magdolen(15), H. Graeff(11), Olaf G. Wilhelm(8), Nadia Harbeck(7), Anke Benge(7), Hans‐Jürgen Wester(5), Markus Schwaiger(5), Achim Krüger(5), Markus Nieberler(4), Marion Kiechle(4), Barbara Schmalfeldt(4), Ernst Lengyel(4), Sandra Hapke(4), Rudolf Napieralski(4), Daniela Lössner(4), Tobias G. Kapp(3), Stefanie Neubauer(3), Oleg V. Maltsev(3)